

FREIBURG February 1st, 2024

German medical technology innovator poised to make waves after implantation of a brain chip by Neuralink in a human trial

As it prepares for the next stage of its groundbreaking device for the treatment of stroke, CorTec GmbH, a pioneering German medical technology company, is poised to make significant strides in the field of neurotechnology.

CorTec is eager to highlight its own advancements in the field, following Neuralink's recent announcement of the first human implantation of its implantable chip. The company is proud to announce that its cutting-edge [Brain Interchange System](#) will enter the first phase of human testing in the coming months. With this significant milestone, CorTec aims to demonstrate its commitment to innovation and improvement of existing therapies.

The Brain Interchange System represents a major leap forward in implanted neurotechnology. By continuously monitoring the brain's state, it accurately assesses each patient's individual therapeutic needs before precisely delivering optimal electrical stimulation therapy. The system is designed for the treatment of neural network disorders, such as epilepsy, schizophrenia, and Parkinson's disease.

The company invites journalists and members of the press to follow the progress of the Brain Interchange and witness the transformative impact it promises to have on the field of neuromodulation. In addition, CorTec GmbH is offering exclusive interview opportunities with its Chief Technology Officer, Dr. Martin Schüttler, to provide in-depth insight into the technology behind the Brain Interchange System and the company's vision for the future of neuromodulation.

About CorTec

CorTec was founded in 2010 in Freiburg, Germany. In the summer of 2018, the company, with currently about 70 employees, moved to new premises with around 400 square meters of laboratories and clean rooms for development and production. Based on [Brain Interchange® Technology](#), CorTec develops and markets neurotechnological components that enable communication with the nervous system such as electrodes, hermetic encapsulations, software or electronics. CorTec's closed-loop implant platform technology Brain Interchange® is designed for measuring and stimulating brain activity in long-term use. CorTec thus offers the necessary cornerstones for the development of innovative personalized therapies for various neural diseases such as stroke rehabilitation, epilepsy, Parkinson's or applications in the field of bioelectronic medicine.

The proprietary *AirRay*® electrode technology developed by CorTec for use in the central and peripheral nervous system is an important component of this system. With [AirRay® Cortical Electrode](#), a portfolio of strip and grid electrodes has now received market clearance in the USA for clinical use in the central nervous system.

Contact:

CorTec GmbH
Dr. Oliver Bärtl (CEO), Dr. Martin Schüttler (CTO)
Neuer Messplatz 3
79108 Freiburg – Germany
Fon.: +49 (0)761 70 888 100
Fax.: +49 (0)761 70 888 399

Media Contact:

Carolina Remke – Head of Marketing
pr@cortec-neuro.com
www.cortec-neuro.com